Micron Biomedical Inc.

Micron Biomedical Inc., an Atlanta-based for-profit company, manufactures microneedle patch medical devices for federal health research and public health procurement as a prime contractor, with no subcontract footprint and no set-aside designations across its federal work.

Micron Biomedical's customer base concentrates entirely within the Department of Health and Human Services. The National Institute of Allergy and Infectious Diseases (NIAID) anchors the highest-dollar work: a $4.5 million definitive contract awarded July 1, 2026, for development of a toll-like receptor 5 agonist dissolving microneedle patch for radiation and nuclear medical countermeasures and biodosimetry devices, running through June 30, 2029 on a cost-plus-fixed-fee basis. The CDC Pittsburgh office holds the remaining seven awards (100% of all awards by count, but only $1.6 million combined potential value), consisting primarily of firm-fixed-price purchase orders for microneedle patch procurement at $250 thousand per award, with the most recent issued September 1, 2024, and ultimate completion August 31, 2026. The divergence between customer rankings reflects NIAID's single large development contract versus CDC's repeated small-dollar procurement orders for manufactured devices. Work is performed in Atlanta, Georgia.

The vendor's award footprint spans eight federal contracts since 2016, with one award in 2019, one in 2020, one in 2023, one in 2024, and one in 2026 — a sparse, episodic pattern with minimal activity trajectory. Combined potential value stands at $6.1 million, of which $3.1 million is obligated. Only one award ($250 thousand to CDC) reaches ultimate completion within the next twenty-four months. NAICS classification centers on biotechnology research and development, with secondary work in life-sciences technical consulting and manufacturing machinery.